Long-Circulating Polymeric Nanoparticles for Drug and Gene Delivery to Tumors

[1]  R. Mehvar.  Dextrans for targeted and sustained delivery of therapeutic and imaging agents. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[2]  M. Papisov,et al.  Why do Polyethylene Glycol-Coated Liposomes Circulate So Long?: Molecular Mechanism of Liposome Steric Protection with Polyethylene Glycol: Role of Polymer Chain Flexibility , 1994 .

[3]  M. Freedman,et al.  Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin , 2005, Cancer Gene Therapy.

[4]  S. Zalipsky.  Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. , 1995, Bioconjugate chemistry.

[5]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[6]  S. B. Tiwari,et al.  Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery , 2005, Technology in cancer research & treatment.

[7]  M. Amiji,et al.  Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. , 2005, Bioconjugate chemistry.

[8]  V. Torchilin.  Polymer-coated long-circulating microparticulate pharmaceuticals. , 1998, Journal of microencapsulation.

[9]  T. Park,et al.  Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). , 2005 .

[10]  R. Kerbel.  A cancer therapy resistant to resistance , 1997, Nature.

[11]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[12]  F. McCormick,et al.  Cancer gene therapy: fringe or cutting edge? , 2001, Nature Reviews Cancer.

[13]  Mansoor Amiji,et al.  Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.

[14]  C. Lewis,et al.  Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. , 2005, The American journal of pathology.

[15]  Haeshin Lee,et al.  A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[16]  P. Black,et al.  Angiostatin suppresses malignant glioma growth in vivo. , 1998, Cancer research.

[17]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[18]  C Delgado,et al.  The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.

[19]  D. Luo,et al.  Poly(ethylene glycol)-Conjugated PAMAM Dendrimer for Biocompatible, High-Efficiency DNA Delivery , 2002 .

[20]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[21]  A. El-Aneed,et al.  An overview of current delivery systems in cancer gene therapy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Mansoor Amiji,et al.  Long-Circulating Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles for Intracellular Delivery , 2002, Pharmaceutical Research.

[23]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[25]  S. W. Kim,et al.  Development of biomaterials for gene therapy. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  H. Ringsdorf.  Structure and properties of pharmacologically active polymers , 1975 .

[27]  Robert Langer,et al.  Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[29]  H. Maeda,et al.  SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. , 1991, Advanced drug delivery reviews.

[30]  E. Marshall.  Second Child in French Trial Is Found to Have Leukemia , 2003, Science.

[31]  V. Torchilin.  How do polymers prolong circulation time of liposomes , 1996 .

[32]  J. Xiang,et al.  Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors , 2002, Cancer Gene Therapy.

[33]  Ernst Wagner,et al.  Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. , 2003, Bioconjugate chemistry.

[34]  M. Manfait,et al.  Elevation of glucosylceramide in multidrug‐resistant cancer cells and accumulation in cytoplasmic droplets , 2001, International journal of cancer.

[35]  I. Maclachlan,et al.  Long-circulating vectors for the systemic delivery of genes. , 2001, Current opinion in molecular therapeutics.

[36]  Sally Lehrman,et al.  Virus treatment questioned after gene therapy death , 1999, Nature.

[37]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[38]  M C Davies,et al.  Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Mansoor Amiji,et al.  Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. , 2005, Journal of pharmaceutical sciences.

[40]  K. Ulbrich,et al.  Steric stabilization of poly-L-Lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. , 2000, Bioconjugate chemistry.

[41]  K. Ulbrich,et al.  A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. , 1999, European journal of cancer.

[42]  E. Wagner,et al.  Tumor targeting with surface-shielded ligand--polycation DNA complexes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[43]  J. Kopeček,et al.  Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. , 2003, Bioconjugate chemistry.

[44]  Mansoor M. Amiji,et al.  Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles , 2003, AAPS PharmSci.

[45]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[46]  Mansoor Amiji,et al.  Biodistribution and Targeting Potential of Poly(ethylene glycol)-modified Gelatin Nanoparticles in Subcutaneous Murine Tumor Model , 2004, Journal of drug targeting.

[47]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[48]  H. Maeda,et al.  Tumoritropic and lymphotropic principles of macromolecular drugs. , 1989, Critical reviews in therapeutic drug carrier systems.

[49]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[50]  G. Denardo,et al.  Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. , 2005, Bioconjugate chemistry.

[51]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.